Exactly runner, its the consistency of the patches. They said that they didnt want to leave anything to chance in the phase 2/3 trials and although they could produce in-house the lower level of consistency could jeapordise the trials.
it's the right move. At the serious phase of development you dont want to be cutting corners. And the added advantage is that the patches can be used for commercial rollout almost immediately should pahse 2/3 trials prove successful.
phosphagenics collaborates with 3m to develop , page-31
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.001(20.0%) |
Mkt cap ! $9.507M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $408 | 154.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 61 | 90794613 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 54998583 | 13 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| AVE (ASX) Chart |